- Home
- FHTX
FHTX
Foghorn Therapeutics Inc.
as 05-15-2025 9:50am EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | $12.63 | AVG Volume (30 days): | 115.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.94 - $10.25 | Next Earning Date: | 05-14-2025 |
| Revenue: | $23,504,000 | Revenue Growth: | -30.66% |
| Revenue Growth (this year): | 29.99% | Revenue Growth (next year): | 2.59% |
Latest Foghorn Therapeutics Inc. News
FHTX Breaking Stock News: Dive into FHTX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
GlobeNewswire
a day ago
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
PR Newswire
9 days ago
Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development
GlobeNewswire
10 days ago
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
GlobeNewswire
14 days ago
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
GlobeNewswire
17 days ago
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
GlobeNewswire
a month ago
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
GlobeNewswire
2 months ago
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
Compare FHTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FHTX Foghorn Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.